Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drugstore.com to absorb SkinStore.com

This article was originally published in The Tan Sheet

Executive Summary

The online retailer will acquire SkinStore.com owner Salu Inc. for $36 million and move "one step closer toward achieving our goal of becoming the leading online retailer of beauty and spa products," drugstore.com says. The Bellevue, Wash.-based firm on Dec. 28 said it intends to close the half-cash, half-stock deal in the first quarter of 2010. SkinStore.com, which carries skin health supplements, sun care products and clinical skin care items, will complement the higher-end cosmetics in the Beauty.com portal, which drugstore.com acquired in 2000 (1"The Tan Sheet" May 1, 2000). Salu, which will continue to operate in Sacramento, Calif., is expected to generate $40 million in revenue and $500,000 in net income for 2009

You may also be interested in...



Drugstore.com Traffic Up 20-30% Since Amazon.com Partnership - Neupert

Drugstore.com's strategic partnership with Amazon.com has increased site traffic 20%-30% since the launch of a "Health & Beauty" tab linking the two sites, drugstore.com Chairman and CEO Peter Neupert reported in an April 24 call with securities analysts.

Dr Reddy’s Knocked Back On Rituximab In US

Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.

Sandoz And Samsung Celebrate Stelara Rival’s EU Approval

Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103656

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel